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Use of MRI in the diagnosis of fetal brain abnormalities
in utero (MERIDIAN): a multicentre, prospective
cohort study. Griffiths PD, Bradburn M, Campbell MJ,
Cooper CL, Graham R, Jarvis D, Kilby MD, et al.;
MERIDIAN collaborative group. Lancet. 2016 Dec 14.
pii: S0140-6736(16)31723-8. doi:10.1016/S0140-6736(16)
31723-8. [Epub ahead of print].
Fetal brain abnormalities occur in approximately 3 in
1000 pregnancies and fetal imaging with ultrasonography
has been the mainstay and first level of investigation for
many years. Previous studies have suggested that in utero
MRI (iuMRI) might be useful as an adjunct to ultrasound
for detecting brain anomalies, but uncertainty remains
regarding the extent of diagnostic and clinical impact.
This prospective, multicenter, cohort study was aimed at
providing information on diagnostic performance, clinical
impact and patient acceptability of iuMRI. Pregnant
women aged 16 years or older whose fetus had a brain
abnormality detected by ultrasound at a gestational age of
18 weeks or more were considered eligible and had a
iuMRI done within 14 days of ultrasound. The cohort was
subdivided by gestation into two subgroups: 18–24 weeks
(n = 369) fetuses, which represented the subgroup of
specific interest, and C24 weeks fetuses (n = 201). Gold
standard for outcome was the neuroanatomical diagnosis
from postnatal neuroimaging studies done up to the age of
6 months, or autopsy/postmortem MRI in case of preg-
nancy termination, stillbirth or neonatal death. The authors
assumed that ultrasonography would achieve an accurate
and complete diagnosis of brain abnormalities in 70% of
cases and tested the hypothesis that it would increase to at
least 80% with iuMRI, with iuMRI and ultrasound being
concordant (correctly and incorrectly) in 70% of cases
overall.
In-utero MRI increased the diagnostic accuracy by 23%
(95% CI 18–27) in the 18–24 weeks group and by 29%
(95% CI 23–36) in the C24 weeks (p\ 0.0001 for both
groups). The overall diagnostic accuracy was 68% for
ultrasound and 93% for iuMRI (difference 25, 95% CI
21–29). The proportion of high confidence diagnoses
increased by 13% after iuMRI (from 82 to 95%) and there
were fewer high confidence but incorrect diagnoses after
iuMRI than ultrasound (6 vs. 22% of the total number of
cases), limiting the possible inappropriate change of man-
agement in these cases.
In-utero MRI was considered to provide additional
diagnostic information in 49% of cases by the referring fetal
medicine expert and to change itself the prognostic infor-
mation in at least 20% of cases. Of note, the contribution of
the iuMRI to the final choice of management was felt by the
clinician to be ‘‘significant’’ in 26% of cases, of ‘‘major
influence’’ in 6% of cases and ‘‘decisive’’ in 3% of cases.
Furthermore, the overall acceptability of the iuMRI was
high, with at least 95% of women saying they would
undergo an iuMRI study in a future pregnancy, if needed. In
contrast to previous studies and systematic reviews, this
study has a prospective design, is appropriately powered and
does not exclude any type of fetal brain abnormality. Even if
it has to be noted that the expertise of the MRI radiographers
doing the examinations is likely to have contributed to the
high completion rate of iuMRI, this study clearly indicates
that iuMRI improves the diagnostic accuracy and confidence
for fetal brain anomalies. This leads, in turn, to prognosis
and management changes in a high proportion of cases. This
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findings, along with the high patient acceptability, lead to
the proposal that any fetus with a suspected brain abnor-
mality on ultrasound should have iuMRI to better counsel
the patients and guide management.
Prenatal findings in children with early postnatal
diagnosis of CHARGE syndrome. Busa T, Legendre M,
Bauge M, Quarello E, Bretelle F, Bilan F, et al. Prenat
Diagn. 2016 Jun;36(6):561-7. doi:10.1002/pd.4825. [Epub
2016 May 12].
CHARGE syndrome is a multiple congenital anomaly
syndrome characterized by the association of the following
main features: ocular coloboma (C), heart disease (H),
choanal atresia (A), retardation of growth and/or develop-
ment (R), genitourinary defects and/or hypogonadism (G),
and ear anomalies with or without deafness (E). Estimated
incidence varies from 1/8500 to 1/15,000 live births. This
syndrome is known to be caused by autosomal dominant
mutations in CHD7, which is currently the only gene found
to be associated with the syndrome and is found in 90–95%
of patients with a clinical diagnosis. In the majority of
cases the mutation is de novo. Neonates with CHARGE
syndrome often have multiple life-threatening medical
conditions, and brainstem and cardiac dysfunction are a
major cause of morbidity. Nevertheless, the diagnosis is
extremely challenging antenatally and is rarely established
in utero. The aim of this study was to report data regarding
pregnancy of children born with CHARGE syndrome and
severe neonatal presentation, in order to improve in utero
diagnosis and neonatal management.
Prenatal findings of 12 children with CHARGE syn-
drome diagnosed in the first 3 months and with a confirmed
CHD7 mutation testing were collected. Authors retrieved
data on prenatal ultrasounds (US), fetal supplementary
investigations (echocardiography, fetal brain magnetic
resonance imaging and fetal karyotyping) and results of
postnatal evaluation.
CHARGE syndrome was suspected in three fetuses but
could not be confirmed despite additional examinations.
Fetus 1 presented the association of unilateral cleft lip and
intrauterine growth restriction (IUGR) and external ear
anomalies. In fetus 2, atrioventricular septal defect (AVSD),
dilated ureters, and external ear anomaly were diagnosed.
Choanal atresia was also suspected. Fetus 3 had bilateral
cleft lip. In four other patients, US survey showed various
congenital malformations, but CHARGE syndrome was not
suspected before birth. In the five remaining patients the
prenatal US assessment was considered normal.
Clinical diagnosis was made at birth in 10 babies. Ten
out of the 12 babies (83%) needed supportive care during
the neonatal period. The mortality was 57% (4/7) in the
group with abnormal findings during pregnancy and 20%
(1/5) in the group with normal prenatal findings.
Congenital heart disease (CHD) was present in 10 out of
12 babies (83%), which is consistent with data from the
literature (74–76%). Nevertheless, excluding patent ductus
arteriosus (PDA) that is overrepresented in CHARGE
syndrome (which by definition, cannot be diagnosed during
pregnancy), only four children were affected by CHD
(33%) in the present series. Of these, two were diagnosed
in utero (one tetralogy of Fallot and one AVSD) and two
after birth (one atrial septal defect and one aortic coarcta-
tion). Among other major features of CHARGE syndrome,
ocular coloboma, choanal atresia, malformed external ears,
cleft lips, arhinencephaly, and semicircular canal agenesis
are potentially detectable in utero with scans and/or fetal
MRI. Ocular coloboma was present in all but one children
at birth, was never detected in utero. Interestingly, two
newborns had severe microphthalmia in addition to the
coloboma, and this finding is potentially detectable ante-
natally. Intrauterine growth restriction complicated two
pregnancies and is thus compatible with the diagnosis. In
addition, four fetuses in the series had 22q11.2 deletion
screening in utero, since many findings can overlap with
this syndrome. Therefore, authors proposed that CHARGE
syndrome should be considered in fetus presenting with the
association of CHD and thymus agenesis and normal
22q11.2 deletion screening. Validation of CHARGE syn-
drome diagnosis by CHD7 screening is feasible in utero if
the diagnosis is suspected. Most mutations are truncating,
missense mutations are less frequent, and large deletions,
accessible to array-CGH, are rare. Therefore, array-CGH
does not allow CHARGE syndrome diagnosis in the
majority of cases.
In conclusion, diagnosis of CHARGE syndrome remains
difficult during pregnancy. If the suspicion of CHARGE
syndrome is raised in utero, a careful ultrasound exami-
nation is recommended to identify external ear deformities,
choanal atresia, or microphthalmia. Fetal brain magnetic
resonance imaging can be helpful, but a normal result does
not exclude the diagnosis. When CHARGE syndrome is
highly suspected, CHD7 molecular analysis should be
considered to confirm the diagnosis.
International standards for symphysis-fundal height
based on serial measurements from the Fetal Growth
Longitudinal Study of the INTERGROWTH-21st Pro-
ject: prospective cohort study in eight countries.
Papageorghiou AT, Ohuma EO, Gravett MG, Hirst J,
da Silveira MF, Lambert A, et al.; International Fetal
and Newborn Growth Consortium for the 21st Century
(INTERGROWTH-21st). BMJ. 2016 Nov 7;355:i5662.
doi:10.1136/bmj.i5662.
Assessment of fetal growth is one of the cornerstones of
antenatal care, in order to identify small and large for
gestational age fetuses at increased risk of perinatal
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morbidity and mortality. In low risk pregnancies, serial
measurement of symphysis-fundal height (SFH) is widely
recommended as a simple, inexpensive, first level screen-
ing tool and very often is the only available technique to
assess fetal growth in low income settings. The sensitivity
of SFH measurement to detect small for gestational age
fetuses shows a wide variability, ranging from 17 to 93%.
There is also marked study heterogeneity mainly due to the
variety of methods used, including varying thresholds for
defining small for gestational age and the use of multiple
SFH charts. Therefore, the aim of this study was to create
international symphysis-fundal height standards derived
from pregnancies of healthy women with good maternal
and perinatal outcomes, in order to improve the care
offered to women worldwide. INTERGROWTH-21st was
a multicentre, multiethnic, prospective longitudinal obser-
vational population study, conducted between 2009 and
2014 in eight countries (urban areas in Brazil, China, India,
Italy, Kenya, Oman, UK, and USA). Healthy women with a
naturally conceived singleton pregnancy, and who met the
individual inclusion criteria, were prospectively recruited.
Gestational age was estimated on the basis of the last
menstrual period provided that the date was certain, and the
menstrual age agreed (within 7 days) with a standardized
measurement of fetal crown rump length at
9 ? 0–13 ? 6 weeks’ gestation. Symphysis-fundal height
was measured every 5 weeks from 14 weeks’ gestation
until birth using standardized methods and dedicated
research staff that was blinded to the symphysis-fundal
height measurements by turning the tape measure, such that
numbers were not visible during examination. Pregnancies
complicated by fetal death or congenital abnormality,
catastrophic or severe medical conditions were excluded.
Maternal smoking also represented an exclusion criterion.
The best fitting curve was selected using second-degree
fractional polynomials and further modelled in a multilevel
framework to account for the longitudinal design of the
study.
13,108 women were screened in the first trimester and
4607 (35.1%) met the study entry criteria. Of the eligible
women, 4321 (93.8%) had pregnancies without major
complications and delivered live singletons without con-
genital malformations. Symphysis-fundal height measure-
ments increased almost linearly with gestational age. Data
were used to determine fitted 3rd, 50th and 97th centile
curves, which showed excellent agreement with observed
values. Analysis of the duplicate SFH measurements
obtained from all women showed that the 95% limits of
agreement were about 1.5 cm.
These international, prescriptive standards, which describe
optimal growth, have the potential to improve pregnancy
outcomes by reducing the wide range in sensitivity for the
detection of small for gestational age. Therefore, the use of
the new international SFH standards in combination with
standardized measurement methodology to unify and
improve clinical practice is highly recommended.
Printable chart is available online at https://intergrowth21.
tghn.org/under ‘‘INTERGROWTH Standards & Tools’’.
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